Diabetes drug may double as brain protector in new trial
NCT ID NCT07694596
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study investigates whether SGLT2 inhibitors, a class of diabetes medications, can slow cognitive decline in people aged 50 and older with type 2 diabetes. Participants are randomly assigned to receive either standard diabetes care plus an SGLT2 inhibitor (empagliflozin or dapagliflozin) or standard care alone. Over 12 months, researchers measure changes in executive function, memory, and other cognitive abilities, along with brain imaging and blood markers. The goal is to see if these drugs offer brain benefits beyond blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitor (empagliflozin or dapagliflozin)
- What this could lead to
- If successful, this could show that a common diabetes drug also helps protect the brain from cognitive decline in people with type 2 diabetes.
- What could go wrong
- This is a relatively small, early-stage trial with 200 participants, so results may not apply to everyone. The cognitive benefits are uncertain, and side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COGNITIVE DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Health Center
Koper, 6000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Student pharmacists may hold the key to better diabetes control in older asian adults
- Spotting the vulnerable: a risk score for post-surgery brain fog in the elderly
- Can a blood vessel drug beat aspirin at preventing heart attacks in diabetes?
- Special forces veterans test Psychedelic-Device combo for PTSD and brain injury
- New Dual-Action drug aims to tackle fatty liver where semaglutide falls short
- Can a 12-Week exercise program boost brain and body health in older adults with diabetes?